Clinical trials: New opportunities

Sandra Bond Chapman; Carl W. Cotman; Howard M. Fillit; Michela Gallagher; Christopher H. Van Dyck

doi:10.1093/gerona/gls126

Clinical trials: New opportunities

Sandra Bond Chapman, Carl W. Cotman, Howard M. Fillit, Michela Gallagher, Christopher H. Van Dyck

Krieger School of Arts and Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and interventions that are based on findings in epidemiology, studies in aged animals, and in vitro research. In addition, since aging is the primary risk factor for Alzheimer's disease, these studies also have implications as interventions for prevention and treatment. As a field of research, new knowledge regarding the causes and mechanisms of cognitive aging are ripe for translation into human studies, with the application of this knowledge leading the development of interventions and therapeutics for the prevention of cognitive decline in old age and Alzheimer's disease.

Original language	English (US)
Pages (from-to)	773-780
Number of pages	8
Journal	Journals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume	67 A
Issue number	7
DOIs	https://doi.org/10.1093/gerona/gls126
State	Published - Jun 15 2012

Keywords

Alzheimers
Clinical trial
Cognition
Cognitive aging

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/gerona/gls126

Cite this

@article{b47264dcda8c4c10b84bbb71b756035f,

title = "Clinical trials: New opportunities",

abstract = "Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and interventions that are based on findings in epidemiology, studies in aged animals, and in vitro research. In addition, since aging is the primary risk factor for Alzheimer's disease, these studies also have implications as interventions for prevention and treatment. As a field of research, new knowledge regarding the causes and mechanisms of cognitive aging are ripe for translation into human studies, with the application of this knowledge leading the development of interventions and therapeutics for the prevention of cognitive decline in old age and Alzheimer's disease.",

keywords = "Alzheimers, Clinical trial, Cognition, Cognitive aging",

author = "Chapman, {Sandra Bond} and Cotman, {Carl W.} and Fillit, {Howard M.} and Michela Gallagher and {Van Dyck}, {Christopher H.}",

year = "2012",

month = jun,

day = "15",

doi = "10.1093/gerona/gls126",

language = "English (US)",

volume = "67 A",

pages = "773--780",

journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",

issn = "1079-5006",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Clinical trials

T2 - New opportunities

AU - Chapman, Sandra Bond

AU - Cotman, Carl W.

AU - Fillit, Howard M.

AU - Gallagher, Michela

AU - Van Dyck, Christopher H.

PY - 2012/6/15

Y1 - 2012/6/15

N2 - Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and interventions that are based on findings in epidemiology, studies in aged animals, and in vitro research. In addition, since aging is the primary risk factor for Alzheimer's disease, these studies also have implications as interventions for prevention and treatment. As a field of research, new knowledge regarding the causes and mechanisms of cognitive aging are ripe for translation into human studies, with the application of this knowledge leading the development of interventions and therapeutics for the prevention of cognitive decline in old age and Alzheimer's disease.

AB - Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and interventions that are based on findings in epidemiology, studies in aged animals, and in vitro research. In addition, since aging is the primary risk factor for Alzheimer's disease, these studies also have implications as interventions for prevention and treatment. As a field of research, new knowledge regarding the causes and mechanisms of cognitive aging are ripe for translation into human studies, with the application of this knowledge leading the development of interventions and therapeutics for the prevention of cognitive decline in old age and Alzheimer's disease.

KW - Alzheimers

KW - Clinical trial

KW - Cognition

KW - Cognitive aging

UR - http://www.scopus.com/inward/record.url?scp=84863640622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863640622&partnerID=8YFLogxK

U2 - 10.1093/gerona/gls126

DO - 10.1093/gerona/gls126

M3 - Article

C2 - 22570132

AN - SCOPUS:84863640622

SN - 1079-5006

VL - 67 A

SP - 773

EP - 780

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

IS - 7

ER -

Clinical trials: New opportunities

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this